The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Actinogen Medical (ACW) appoints Avance Clinical and Paratus Clinical to assist with its dose ranging study
  • The study is set to be conducted at four Paratus clinics in Australia, enrolling 105 healthy volunteers over the age of 50 who will be dosed with Actinogen’s lead drug candidate, Xanamen
  • The company also finalises its agreement with Australian neuroscience technology company Cogstate to use its Neuropsychological Test Battery in the XanaMIA study
  • Actinogen Medical is up 7.69 per cent, trading at 14 cents at 11:45 am AEST

Actinogen Medical (ACW) has appointed Avance Clinical and Paratus Clinical to assist with its dose ranging study.

The leading clinical research organisations will assist in the conduct, management and recruitment of the XanaMIA Part A dose ranging study.

The study will be conducted at four Paratus clinics in Australia, enrolling 105 healthy volunteers over the age of 50, using a budget of around $850,000. The volunteers will be given a dose ranging from between 5 milligrams and 10 miligrams of Xanamem to confirm the minimum effective dose.

Xanamem is Actinogen’s lead drug candidate, which is designed the block the production of cortisol, the stress hormone, in the brain — a hormone generally associated with cognitive decline in Alzheimer’s disease when elevated.

Avance will then manage the study, using a total work order of roughly $1.25 million.   

Additionally, the company has finalised its agreement with Australian neuroscience technology company Cogstate to use its Neuropsychological Test Battery in the XanaMIA study.

Actinogen finalised a work order with Cogstate in April for around US$300,000 (approximately A$400,000) to use its Neuropsychological Test Battery, a modern platform designed to deliver highly sensitive cognition tests.

This announcement comes after Actinogen recently received approval from the Bellberry Human Research Ethics Committee for XanaMIA and is expected to begin enrolling patients in July 2021.

Actinogen Medical was up 7.69 per cent, trading at 14 cents at 11:45 am AEST.  

ACW by the numbers
More From The Market Online

4DMedical (ASX:4DX) to take part in US Veterans study into lung damage

It's called a burn pit: where members of the US armed forces dump unwanted and contaminated…

Proteomics International subsidiary secures European patent for OxiDx technology

Proteomics International Laboratories (ASX: PIQ) has announced that its subsidiary, OxiDx, has secured a patent across…

Recce Pharmaceuticals leads the way in collaborative Anti-Infective research

Recce Pharmaceuticals (ASX:RCE) has announced the ongoing initiatives within its Anti-Infective Research (AIR) Unit situated at…

Telix Boosts U.S. Presence with IsoTherapeutics Acquisition

Melbourne-based Telix Pharmaceuticals (ASX: TLX) has sealed the deal to acquire IsoTherapeutics Group, LLC